Document is current
Any future updates will be listed below
-
Authors
Miller, D. Claire https://orcid.org/0000-0001-6144-8595
Chawla, Devika https://orcid.org/0000-0002-9727-6833
Johansen Taber, Katherine https://orcid.org/0000-0003-3051-2667
Payne, Jennifer L. https://orcid.org/0000-0003-0006-1199
Del Tredici, Andria L. https://orcid.org/0000-0002-9746-7728
-
Funding
Funding for this research was provided by:
Myriad Genetics
- License Information
-
More Information
Article History
Received: 15 November 2024
Accepted: 13 May 2025
First Online: 4 June 2025
Declarations
:
: This study utilized de-identified data obtained in compliance with HIPAA regulations. Consequently, the study did not meet the U.S. Department of Health and Human Services' definition of research involving human subjects (45 CFR 46.102). Therefore, it was not submitted for Institutional Review Board approval, nor did it require consent to participate. Additionally, the study adhered to the ethical principles outlined in the Declaration of Helsinki.
: Not applicable.
: D.C. Miller, D. Chawla, K. J. Taber, and A.L. Del Tredici are employees and shareholders of Myriad Genetics, Inc. J.L. Payne receives research support from NIMH and Janssen Pharmaceuticals. J.L. Payne has two patents: “Epigenetic Biomarkers of Postpartum Depression” and “Epigenetic Biomarkers of Premenstrual Dysphoric Disorder and SSRI Response.” J.L. Payne has Founder's Stock options in Dionysus Health and has received consulting fees from SAGE Therapeutics, Biogen, Flo Health, Pure Tech, Brii Biosciences, and Merck.
